Artificial Intelligence in Drug Design: A Webinar by International Business Machines (IBM)
Online via Webex
The School of Arts and Sciences, in collaboration with International Business Machines (IBM), is organizing a webinar on “Artificial Intelligence in Drug Design” presented by IBM’s Wendy Cornell and Mary Sylvester.
Click here to register.
The webinar aims to provide an understanding on the role of Artificial Intelligence, Machine Learning and Deep Learning in today’s healthcare system. It will also explore how generative AI can be used to create rather than just classify, recognize the value of real world evidence such as electronic healthcare records, and provide an understanding about probabilistic disease progression modeling and signal processing in various diseases.
- Introduction to AI, Machine Learning, and Deep Learning
- Data requirements
- Small molecule drug design using generative AI
- Estimating the causal effect of an intervention from RWD
- Extraction of information related to Drug Safety Surveillance from Electronic Health Record Notes
- Deep Learning for Improved Diagnosis, Treatment and Management of Epilepsy
- Probabilistic Disease Progression Modeling for Huntington’s Disease
- NLP & Signal Processing for Neuropsychiatric Assessment
- AI & Imaging for Neuropsychiatric Assessment
- Automatic Assessment of Parkinson’s Disease Motor Symptoms
- Predicting Breast Cancer by Applying Deep Learning to Multi-modal Data - Presented by Dr. Ahmad Mahdi - LAU Gilbert and Rose-Marie Chagoury School of Medicine
- Role of AI in Telehealth